Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2026 07:00 ET | Source: Sitryx Therapeutics

First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026

First-in-human healthy volunteers trial showed SYX-5219 was safe and well toleratedSystemic immunomodulation of type 2 inflammation demonstrated with reduction in serum CCL17/TARC Phase 1b trial in...
October 02, 2025 07:00 ET | Source: Sitryx Therapeutics

Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic dermatitis

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseasesPhase 1b trial to investigate the safety, tolerability and initial...